Canaccord Genuity Thinks Emblem Corp’s Stock is Going to Recover

By Carrie Williams

On October 11, an analyst has provided a rating update for the Healthcare company, Emblem Corp (TSXV: EMC). Analyst Neil Maruoka from Canaccord Genuity reiterated a Buy rating, with a C$2.50 price target on October 11.

According to, Maruoka is a 2-star analyst with an average return of 0.0% and a 41.0% success rate. Maruoka covers the Healthcare sector, focusing on stocks such as Merus Labs International, Aurinia Pharmaceuticals, and Cardiome Pharma Corp.

Emblem Corp has an analyst consensus of Moderate Buy, with a price target consensus of C$2.13.

The company has a one-year high of C$4.60 and a one-year low of C$1.50. Currently, Emblem Corp has an average volume of 254.2K.

Emblem Corp. engages in the provision of pharmaceutical development related to cannabis products. Its activities include cultivation and sale of medical marijuana. The company was founded in 2014 and is headquartered in Toronto, Canada.

The company’s shares closed on Thursday at C$1.95, close to its 52-week low of C$1.50.